Trials / Withdrawn
WithdrawnNCT06147856
A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of mRNA 3210 in Participants With Phenylketonuria
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main goal of this study is to assess the safety, and tolerability of multiple doses of mRNA-3210 in participants with phenylketonuria (PKU).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mRNA-3210 | IV infusion |
Timeline
- Start date
- 2024-03-29
- Primary completion
- 2026-08-10
- Completion
- 2027-08-05
- First posted
- 2023-11-28
- Last updated
- 2024-10-22
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06147856. Inclusion in this directory is not an endorsement.